Popular Filters
Trials for Non-Small Cell Lung Cancer Patients
CAR T-cell Therapy
LYL797 for Breast and Lung Cancer
This trial is testing a new treatment called LYL797, which uses modified immune cells to target and kill hard-to-treat breast and lung cancer cells. The study aims to find a safe dose and see how well it works in patients whose cancers have not responded to other treatments.
Trials for NSCLC Patients
CAR T-cell Therapy
LYL797 for Breast and Lung Cancer
This trial is testing a new treatment called LYL797, which uses modified immune cells to target and kill hard-to-treat breast and lung cancer cells. The study aims to find a safe dose and see how well it works in patients whose cancers have not responded to other treatments.
Trials for Metastatic Patients
CAR T-cell Therapy
LYL797 for Breast and Lung Cancer
This trial is testing a new treatment called LYL797, which uses modified immune cells to target and kill hard-to-treat breast and lung cancer cells. The study aims to find a safe dose and see how well it works in patients whose cancers have not responded to other treatments.
Trials With No Placebo
CAR T-cell Therapy
LYL797 for Breast and Lung Cancer
This trial is testing a new treatment called LYL797, which uses modified immune cells to target and kill hard-to-treat breast and lung cancer cells. The study aims to find a safe dose and see how well it works in patients whose cancers have not responded to other treatments.
Frequently Asked Questions
Introduction to nsclc
What are the top hospitals conducting nsclc research?
In the battle against non-small cell lung cancer (NSCLC), several hospitals are leading the charge in pioneering clinical trials. These institutions, located across different regions of the United States, are dedicated to finding new and improved treatments for this aggressive form of lung cancer. In Chandler, a research site is actively conducting two nsclc trials, while in Atlanta and Canton, other research sites are also making significant contributions with their own ongoing investigations. Even established centers like Memorial Sloan Kettering Cancer Center in New york recognize the importance of tackling NSCLC head-on by initiating two active clinical trials of their own. Meanwhile, in Las Vegas at Comprehensive Cancer Centers of Nevada, researchers strive to make advancements through their participation in two current NSCLC trials as well.
NSCLC is the most common type of lung cancer and accounts for approximately 85% of all cases. It often develops in former or current smokers but can also affect individuals who have never smoked before. This condition has a higher survival rate compared to small cell lung cancer but still poses significant challenges due to its ability to spread rapidly within the lungs and potentially metastasize to other organs.
Clinical trials play a critical role in advancing our understanding of NSCLC and developing innovative treatment options that could improve patients' quality of life and overall prognosis. They provide an opportunity for participants to access cutting-edge therapies that may not yet be available through standard treatment methods.
By supporting these hospitals' efforts in conducting active clinical trials focused on NSCLC management, we stand one step closer towards unraveling new breakthroughs that will transform patient care and bring hope to those affected by this devastating disease. Together, we can empower medical progress that holds promise for brighter futures across communities nationwide.
Which are the best cities for nsclc clinical trials?
When it comes to NSCLC clinical trials, several cities stand out as leading centers for research. Boston, Massachusetts offers 14 active trials focusing on treatments like encorafenib, Sasanlimab, and ACY-241. New york, New York follows closely with 11 ongoing studies exploring options such as encorafenib, Sasanlimab, and L-SABR Arm. Los Angeles, California also has 11 active trials investigating treatments like Sasanlimab and novel combinations such as Ceralasertib plus durvalumab therapy. Lastly, Atlanta, Georgia and Bronx, New York each have 8 active trials studying various treatment approaches including AMG 510 and LYL797. These cities provide valuable opportunities for individuals seeking participation in NSCLC clinical trials that could potentially revolutionize the management of this disease.
Which are the top treatments for nsclc being explored in clinical trials?
In the realm of non-small cell lung cancer (NSCLC), clinical trials are actively investigating a few standout treatments. Leading the charge is osimertinib, an impressive drug that has gained attention in recent years. Additionally, pembrolizumab and nivolumab have shown promising results in NSCLC trials, offering hope to patients. These innovative therapies hold great potential for improving outcomes and transforming the landscape of NSCLC treatment.
What are the most recent clinical trials for nsclc?
Promising developments have emerged from recent clinical trials for non-small cell lung cancer (NSCLC), offering hope to patients. In one study, the L-SABR arm showcased encouraging results during its Phase 2 trial, demonstrating the potential of this treatment approach. Additionally, a Phase 3 trial investigated the efficacy of combining ceralasertib with durvalumab in Group A NSCLC patients, highlighting a possible breakthrough combination therapy. Another noteworthy trial focused on evaluating LYL797 in NSCLC patients during its Phase 1 stage. Although still in earlier stages, these studies highlight significant progress towards improving treatment options for NSCLC and enhancing patient outcomes.
What nsclc clinical trials were recently completed?
Recently, several clinical trials in the field of non-small cell lung cancer (NSCLC) have been completed, showcasing advancements in treatment approaches. These trials include a study investigating uproleselan sponsored by Washington University School of Medicine, completed in October 2021. Another trial focused on mRNA-1273 sponsored by the National Cancer Institute (NCI) was concluded in September 2021. Additionally, AgenTus Therapeutics successfully completed their agenT-797 trial in January 2021. These significant developments highlight ongoing efforts to advance NSCLC treatment options and provide hope for patients battling this form of lung cancer.